An Evaluation of Wb123 Antibody Elisa in Individuals Treated With Ivermectin and Albendazole, and Implementation Challenges in Africa

Show simple item record

dc.contributor.author de Souza, D.K.
dc.contributor.author Owusu, I.O.
dc.contributor.author Otchere, J.
dc.contributor.author Adimazoya, M.
dc.contributor.author Frempong, K.
dc.contributor.author Ahorlu, C.S.
dc.contributor.author Boakye, D.A.
dc.contributor.author Wilson, M.D.
dc.date.accessioned 2019-08-15T09:34:20Z
dc.date.available 2019-08-15T09:34:20Z
dc.date.issued 2017-05
dc.identifier.other DOI: 10.11604/pamj.2017.27.65.11004
dc.identifier.uri http://ugspace.ug.edu.gh/handle/123456789/32011
dc.description.abstract The development of antibody testing for the diagnosis of lymphatic filariasis (LF) is intended to enhance the monitoring and evaluation activities of the Global Program for the Elimination of LF. This is due to the fact that antibody tests are expected to be the most sensitive at detecting exposure to LF compared to antigen that takes longer to develop. To this end a new antibody-based enzyme linked immunosorbent assay (ELISA) to Wuchereria bancrofti antigen Wb123 has been developed and further designed into a point of care rapid diagnostic test, under evaluation. In pre-treatment surveys, individuals were tested for antigen using the immuno-chromatographic test (ICT) card, and night blood microfilariae, after which all positives were treated using Ivermectin and Albendazole. The Wb123 ELISA was tested in antigen positive individuals, three months after they were treated. Samples were also tested for ICT and night blood microfilariae. The results revealed a reduction in microfilariae and ICT prevalence after treatment. Antigen and antibody prevalence increased with age. However, there was no correlation with the antibody responses observed. The mean WB123 antibody titers were higher among ICT positives, but not significantly different from ICT negative persons. While the Wb123 is targeted for use in untreated populations, further evaluations and guidelines will be required to define its use in populations that have undergone treatment for the control of LF. en_US
dc.language.iso en en_US
dc.publisher Pan African Medical Journal en_US
dc.subject Ghana en_US
dc.subject Lymphatic filariasis en_US
dc.subject Wb123 en_US
dc.subject Antibody en_US
dc.subject Antigen Elephantiasis en_US
dc.title An Evaluation of Wb123 Antibody Elisa in Individuals Treated With Ivermectin and Albendazole, and Implementation Challenges in Africa en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

  • Parasitology Department [253]
    The Department of Parasitology conducts research into parasitic diseases of public health importance with the overall goal of reducing their transmission and the heavy disease burden that they impose on affected populations. The Department maintains focus on parasitic diseases in general. These include major diseases such as malaria, and others listed under the Neglected Tropical Diseases (NTD) control initiative such as, lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, trypanosomiasis and leishmaniasis.

Show simple item record

Search UGSpace


Browse

My Account